603 Nadir serum PSA level can predict the early progression of androgen independent prostate cancer in intermittent androgen deprivation therapy

Shin, John; Chai, Shengwu; Choi, H.Y.

doi:10.1016/s1569-9056(04)90597-0

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSA level is the most valuable tool for monitoring disease status and the treatment response, especially in patients with advanced metastatic prostate cancer, as shown in many studies [ 1 , 4 , 5 ]. However, the progression of prostate cancer can sometimes occur in the presence of an undetectable or low serum PSA level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Progression of Prostate Cancer Despite an Extremely Low Serum Level of Prostate-Specific Antigen

Lee¹,

Park²,

Kim³

et al. 2010

Korean J Urol

View full text Add to dashboard Cite

A 61-year-old man who had been diagnosed with prostate cancer 9 years ago and had been treated with pelvic irradiation and intermittent androgen deprivation therapy visited the emergency room because of back pain and weakness in both legs. Spine magnetic resonance imaging showed a lumbar epidural mass and spine metastasis. The whole-body workup revealed multiple metastases to the lymph nodes, bone, liver, and lung. The serum prostate-specific antigen was 0.02 ng/ml. He underwent laminectomy, posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from the prostate was diagnosed. The patient underwent 1 cycle of docetaxel-based chemotherapy. More chemotherapy could not be done because of his general weakness. The patient died one month later of multiple organ failure.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The kinetics of PSA after the treatment of prostate cancer make it a sensitive marker for the activity and status of this disease. Many studies have suggested that PSA may be the most valuable factor for predicting the activity and volume of prostate cancer [ 1 ].…”

mentioning

confidence: 99%